CTLA4 and cancer: The inhibition of immune checkpoints, such as programmed death-1 (PD-1) or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), have led to a breakthrough in cancer treatment by releasing the break on cellular anti-tumor immunity [3,27,28,29,30].